Indian Diabetes Market

Indian Diabetes Market

RELEASE DATE
18-Mar-2013
REGION
South Asia, Middle East & North Africa
Research Code: P674-01-00-00-00
SKU: LS00137-SA-MR_16978
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
LS00137-SA-MR_16978

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This research service studies the Indian Diabetes market. It provides the number of Type 1 and Type 2 diabetic patients in India across different age groups and forecasts these numbers up to 2030. It provides a detailed analysis of the two major segments of the market, the insulin market segment and the anti-diabetic medications segment, which includes oral anti-diabetics as well as injectable ones. Drivers and Restraints faced by the participants in this market have been analysed. Based on these, a quantitative analysis and revenue forecast from 2011 up to 2017 has been provided for the total market as well as the two segments: Insulin and Anti-diabetic medications. Finally, strategic recommendations have also been provided.

Table of Contents

Executive Summary

Executive Summary (continued)

Executive Summary—Market Engineering Measurements

Executive Summary—Market Engineering Measurements (continued)

Executive Summary—CEO’s Perspective

Market Overview—Definitions

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Market Overview—Definitions (continued)

Diabetes Overview—Global

Worldwide Diabetes Overview

Market Overview—Key Questions This Study Will Answer

Market Overview—Segmentation

Market Overview—Patient Share Forecast by Treatment Type

Market Overview—Patient Share Forecast by Treatment Type (continued)

Total Diabetes Market: Key Treatment Challenges in India (2011)

Distribution Channels

Southeast Asia Diabetes Overview

Southeast Asia Diabetes Overview (continued)

Drivers and Restraints

Drivers Explained

Drivers Explained (continued)

Drivers Explained (continued)

Drivers Explained (continued)

Drivers Explained (continued)

Restraints Explained

Restraints Explained (continued)

Restraints Explained (continued)

Restraints Explained (continued)

Restraints Explained (continued)

Market Engineering Measurements

Forecast Assumptions

Total Diabetes Market—Revenue Forecast

Revenue Forecast Discussion

Total Diabetes Market—Per cent Revenue Forecast by Segment

Per cent Revenue Forecast by Segment Discussion

Diabetes Population Overview—India

Diabetes Population Overview—India (continued)

Diabetes Population Overview—India (continued)

Patient Share Forecasts

Market Potential

Companies by Product Segment

Competitive Analysis—Market Share

Market Share Analysis

Competitive Environment

Insulin Segment Breakdown

Insulin Segment—Market Engineering Measurements

Insulin Segment—Revenue Forecast

Insulin Segment—Revenue Forecast Discussion

Competitive Analysis—Segment Share

Competitive Analysis—Segment Share

Competitive Environment

Insulin Versus Insulin Analogues

Insulin Versus Insulin Analogues (continued)

R&D Pipeline

R&D Pipeline (continued)

Intermediate-Acting Insulin—Market Engineering Measurements

Intermediate-Acting Insulin—Competitive Analysis

Fast-Acting Insulin—Market Engineering Measurements

Fast-Acting Insulin—Competitive Analysis

Long-Acting Insulin—Market Engineering Measurements

Long-Acting Insulin—Competitive Analysis

Pre-Mixed Insulin—Market Engineering Measurements

Pre-Mixed Insulin—Competitive Analysis

Animal Insulin—Market Engineering Measurements

Animal Insulin—Competitive Analysis

Insulin Delivery

Insulin Delivery (continued)

Insulin Delivery (continued)

Anti-Diabetics Medications Segment Breakdown

Anti-Diabetes Medications Segment—Market Engineering Measurements

Anti-Diabetes Medications Segment—Revenue Forecast

Revenue Forecast Discussion

Competitive Analysis—Segment Share

Competitive Analysis—Segment Share (continued)

Competitive Environment

Biguanides (metformin)

Biguanides (metformin)—Market Engineering Measurements

Biguanides (metformin)

Sulfonylureas

Glimepiride—Market Engineering Measurements

Glimepiride

Glibenclamide—Market Engineering Measurements

Glibenclamide

Gliclazide—Market Engineering Measurements

Gliclazide

Glipizide—Market Engineering Measurements

Glipizide

Alpha-Glucosidase Inhibitors

Voglibose—Market Engineering Measurements

Voglibose—Product Portfolio

Acarbose—Market Engineering Measurements

Acarbose—Product Portfolio

Thiazolidinediones

Rosiglitazone Banned in India

Pioglitazone—Market Engineering Measurements

Pioglitazone—Product Portfolio

Meglitinides

Repaglinide—Market Engineering Measurements

Repaglinide—Product Portfolio

Nateglinide—Market Engineering Measurements

Nateglinide—Product Portfolio

DPP-IV Inhibitors

Sitagliptin—Market Engineering Measurements

Sitagliptin—Product Portfolio

Vildagliptin—Market Engineering Measurements

Vildagliptin—Product Portfolio

Saxagliptin—Market Engineering Measurements

Saxagliptin—Product Portfolio

Linagliptin—Market Engineering Measurements

Linagliptin—Product Portfolio

Exenatide—Market Engineering Measurements

Exenatide—Product Portfolio

Liraglutide—Market Engineering Measurements

Liraglutide—Product Portfolio

Fixed-Dose Combination

Fixed-Dose Combination (continued)

Fixed-Dose Combination (continued)

Fixed-Dose Combination (continued)

Fixed-Dose Combination (continued)

Glimepiride + metformin

Glimepiride + metformin—Market Engineering Measurements

Glimepiride + metformin—Product Portfolio

Sitagliptin + metformin

Sitagliptin + metformin—Market Engineering Measurements

Sitagliptin + metformin—Product Portfolio

Glipizide + metformin

Glipizide + metformin—Market Engineering Measurements

Glipizide + metformin—Product Portfolio

Gliclazide + metformin

Gliclazide + metformin—Market Engineering Measurements

Gliclazide + metformin—Product Portfolio

Glibenclamide + metformin

Glibenclamide + metformin—Market Engineering Measurements

Glibenclamide + metformin—Product Portfolio

Vildagliptin + metformin

Vildagliptin + metformin—Market Engineering Measurements

Vildagliptin + metformin—Product Portfolio

Pioglitazone + metformin

Pioglitazone + Metformin—Market Engineering Measurements

Pioglitazone + metformin—Product Portfolio

Pioglitazone + Glimepiride

Pioglitazone + Glimepiride—Market Engineering Measurements

Pioglitazone + Glimepride—Product Portfolio

Metformin + Voglibose

Metformin + Voglibose—Market Engineering Measurements

Metformin + Voglibose—Product Portfolio

Pioglitazone + metformin + Glimepiride

Pioglitazone + metformin + Glimepiride—Market Engineering Measurements

Pioglitazone + metformin + Glimepiride—Product Portfolio

Future Trends in Diabetes Management

Future Trends in Diabetes Management (continued)

Novo Nordisk

Sanofi Aventis

Eli Lilly

Biocon

Novartis

USV

Lupin

MSD (Merck Sharp & Dohme)

Intas Pharma

Dr Reddy’s

Strategic Recommendations

Strategic Recommendations (continued)

Strategic Recommendations (continued)

Strategic Recommendations (continued)

Strategic Recommendations (continued)

The Last Word—Three Big Predictions

The Last Word—Discussion

Legal Disclaimer

Market Engineering Methodology

Learn More—Next Steps

Related Research
This research service studies the Indian Diabetes market. It provides the number of Type 1 and Type 2 diabetic patients in India across different age groups and forecasts these numbers up to 2030. It provides a detailed analysis of the two major segments of the market, the insulin market segment and the anti-diabetic medications segment, which includes oral anti-diabetics as well as injectable ones. Drivers and Restraints faced by the participants in this market have been analysed. Based on these, a quantitative analysis and revenue forecast from 2011 up to 2017 has been provided for the total market as well as the two segments: Insulin and Anti-diabetic medications. Finally, strategic recommendations have also been provided.
More Information
No Index No
Podcast No
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
WIP Number P674-01-00-00-00
Is Prebook No